Shiga toxins, glycosphingolipid diversity, and endothelial cell injury

Thrombosis and Haemostasis

Volumn 101, Issue 2, 2009, Pages 252-264

  Müthing, Johannes ^a   Schweppe, Christian H ^a,b   Karch, Helge ^a,b   Friedrich, Alexander W ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Interdisciplinary Center for Clinical Research   (Germany)

Author keywords

Endothelial cells; Gb3Cer; MALDI TOF MS; STEC; TLC overlay assay

Indexed keywords

GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; SHIGA TOXIN; CERAMIDE TRIHEXOSIDE; LIGAND; PROTEIN SUBUNIT;

ARTICLE; BINDING ASSAY; BLOODY DIARRHEA; CELL LINE; CELL MEMBRANE; CYTOSOL; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ESCHERICHIA COLI; GOLGI COMPLEX; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIPID RAFT; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TARGET CELL; THIN LAYER CHROMATOGRAPHY; THROMBOSIS; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; ESCHERICHIA COLI INFECTION; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MICROBIOLOGY; MOLECULAR GENETICS; PATHOGENICITY; PATHOLOGY; PEPTIDE MAPPING; PROTEIN CONFORMATION; PROTEIN TRANSPORT; PROTEOMICS; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, THIN LAYER; ENDOCYTOSIS; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LIGANDS; MEMBRANE MICRODOMAINS; MOLECULAR SEQUENCE DATA; PEPTIDE MAPPING; PROTEIN CONFORMATION; PROTEIN SUBUNITS; PROTEIN TRANSPORT; PROTEOMICS; SHIGA TOXINS; SHIGA-TOXIGENIC ESCHERICHIA COLI; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRIHEXOSYLCERAMIDES;

EID: 62449181018     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-05-0317     Document Type: Article

References (174)

1. Karch H, et al. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295: 405-418.
2. Karmali MA. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol Biotechnol 2004; 26: 117-122.
3. Tarr PI, et al. Shiga toxin-producing Escherichia coli and the haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086.
4. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost 2005; 94: 312-318.
5. Barbieri L, et al. Shiga-like toxin I is a polynucleo-tide:adenosine glycosidase. Mol Microbiol 1998; 29: 661-662.
6. Brigotti M, et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J 2002; 16:365-372.
7. Sandvig K. Shiga toxins. Toxicon 2001; 39: 1629-1635.
8. Jackson MP, et al. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett 1987; 44: 109-114.
9. Friedrich AW, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74-84.
10. Friedrich AW, et al. Shiga toxin lc-producing Escherichia coli strains: Phenotypic and genetic characterization and association with human disease. J Clin Microbiol 2003; 41: 2448-2453.
11. Bielaszewska M, et al. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006; 43: 1160-1167.
12. Zhang W, et al. Structural and functional differences between disease-associated genes of enterohaemorrhagic Escherichia coli O111. Int J Med Microbiol 2007; 297: 17-26.
13. Orth D, et al. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 2007; 59: 235-242.
14. Jenkins C, et al. Subtyping of virulence genes in ve-rocytotoxin- producing Escherichia coli (VTEC) other than serogroup O157 associated with disease in the United Kingdom. J Med Microbiol 2003; 52: 941-947.
15. Boerlin P, et al. Association between virulence factors of Shiga toxin-producing Escherichia coli and disease in human, J Clin Microbiol 1999; 37; 497-503.
16. Beutin L, et al. Characterization of Shiga toxin-producing Escherichia coli strains isolated from humans in Germany over a 3-year period. J Clin Microbiol 2004; 42: 1099-1108.
17. Brooks JT, et al. Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983-2002. J Infect Dis 2005; 192: 1422-1429.
18. 1c) in Escherichia coli isolated from humans. J Clin Microbiol 2002; 40: 1441-1446.
19. Bürk C, et al. Identification and characterization of a new variant of Shiga toxin 1 in Escherichia coli ONT:H19 of bovine origin. J Clin Microbiol 2003; 41: 2106-2112.
20. Kuczius T, et al. A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli, Mol Nutr Food Res 2004; 48: 515-521.
21. Schmitt CK, et al. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H strain E32511. Infect Immun 1991; 59: 1065-1073.
22. Jelacic JK, et al. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J Infect Dis 2003; 188: 719-729.
23. Pierard D, et al. Identification of new verocytotox-in type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J Clin Microbiol 1998; 36: 3317-3322.
24. Melton-Celsa AR, et al. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun 1996; 64: 1569-1576.
25. Sonntag AK, et al. Shiga toxin 2e-producing Escherichia coli isolates from humans and pigs differ in their virulence profiles and interactions with intestinal epithelial cells. Appl Environ Microbiol 2005; 71: 8855-8863.
26. Sonntag AK, et al. Pigeons as a possible reservoir of Shiga toxin 2f-producing Escherichia coli pathogenic to humans. Berl Munch Tierarztl Wochenschr 2005; 118: 464-470.
27. Seto K, et al. Biochemical and molecular characterization of minor serogroups of Shiga toxin-producing Escherichia coli isolated from humans in Osaka prefecture. J Vet Med Sci 2007; 69: 1215-1222.
28. van Duynhoven YT, et al. Prevalence, characterisation and clinical profiles of Shiga toxin-producing Escherichia coli in The Netherlands Clin Microbiol Infect 2008; 14: 437-445.
29. Prager R, et al. Diversity of virulence patterns among Shiga toxin-producing Escherichia coli from human clinical cases - need for more detailed diagnostics. Int J Med Microbiol 2005; 295: 29-38.
30. Mellmann A, et al. Analysis of the collection of hemolytic uremic syndrome-associated enterohemorrhagic Escherichia coli (HUSEC). Emerg Infect Dis 2008; 14: 1287-1290.
31. Schmidt H, et al. A new Shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl Environ Microbiol 2000; 66: 1205-1208.
32. Isobe J, et al. Isolation of Escherichia coli O128:HNM harboring stx2f gene from diarrhea patients. Kansenshogaku Zasshi 2004; 78: 1000-1005.
33. Mellmann A, et al. Recycling of Shiga toxin 2 genes in sorbitol-fermenting enterohemorrhagic Escherichia coli O157:NM. Appl Environ Microbiol 2008; 74: 67-72.
34. Bielaszewska M, et al. Shiga toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in humans. Appl Environ Microbiol 2007; 73: 3144-3150.
35. Bielaszewska M, et al. Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm? PLoS ONE 2007; 2:e1024.
36. Friedrich AW, et al. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 2007; 45: 39-45.
37. Bielaszewska M, et al. Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution. Clin Infect Dis 2008; 47: 208-217.
38. Endo Y, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and Shiga toxin on eu-karyotic ribosomes. Eur JBiochem 1988; 171: 45-50.
39. 3. Biochemistry 1998; 37: 1777-1788.
40. Paton JC, Paton AW. Shiga toxin 'goes retro' in human primary kidney cells. Kidney Int 2006; 70: 2049-2051.
41. Sandvig K, et al. Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol 2002; 117: 131-141.
42. Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol 2006; 7: 568-579.
43. Römer W, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007; 450: 670-675.
44. Sandvig K, et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992; 358: 510-512.
45. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol 1996; 4: 147-153.
46. Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty isoform traffic. J Cell Physiol 1998; 177: 646-660.
47. Garred Ø, et al. Furin-induced cleavage and activation of Shiga toxin. I Biol Chem 1995; 270: 10817-10821.
48. Lea N, et al. Proteolytic cleavage of the A subimit is essential for maximal cytotoxicity of Escherichia coli O157:H7 Shiga-like toxin-1. Microbiology 1999; 145: 999-1004.
49. 1, subunit in target cells. Microbiology 2007; 153: 2700-2710.
50. Obrig TG. Shiga toxin mode of action in E. coli O157:H7 disease. Front Biosci 1997; 2: d635-642.
51. Cherla RP, et al. Shiga toxins and apoptosis. FEMS Microbiol Lett 2003; 228: 159-166.
52. Nakao H, Takeda T. Escherichia coli Shiga toxin. J Nat Toxins 2000; 9: 299-313.
53. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome. Semin Thromb Hemost 2001; 27: 207-213.
54. Forsyth KD, et al. Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet 1989; 2: 411-414.
55. Morigi M, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001; 98: 1828-1835.
56. Morigi M, et al. Verotoxin-1 promotes leucocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 1995; 86: 4553-4558.
57. Mulvey G, et al. Affinity purification of Shiga-like toxin I and Shiga-like toxin II. J Microbiol Methods 1998; 32: 247-252.
58. Nakajima H, et al. Single-step method for purification of Shiga toxin-1 B subunit using receptor-mediated affinity chromatography by globotriaosylceram- ide-conjugated octyl sepharose CL-4B. Protein Expr Purif 2001; 22: 267-275.
59. Boulanger J, et al. Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands. Anal Biochem 1994; 217: 1-6.
60. Karch H, Bitzan M. Purification and characterization of a phagc-encoded cytotoxin from an Escherichia coli O111 strain associated with hemolytic-uremic syndrome. Zentralbl Bakteriol Mikrobiol Hyg 1988; 270: 41-51.
61. Karch H, et al. Purified verotoxins of Escherichia coli O157:H7 decrease prostacyclin synthesis by endothelial cells. Microb Pathog 1988; 5: 215-221.
62. Shevchenko A. et al. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 1996; 68: 850-858.
63. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem Rev 2001; 101: 269-295.
64. Fraser ME, et al. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 2004; 279: 27511-27517.
65. Shayman JA, Radin NS. Structure and function of renal glycosphingolipids. Am J Physiol 1991; 260: F291-302.
66. Holgersson J, Jovall PA. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. J Biochem 1991; 110: 120-131.
67. Macher BA, et al. Glycosphingolipids of normal and leukemic human leukocytes. Mol Cell Biochem 1982; 47: 81-95.
68. Gillard BK, et al. Association of glycosphingolipids with intermediate filaments of mesenchymal, epithelial, glial, and muscle cells. Cell Motil Cytos-keleton 1992; 21: 255-271.
69. Feizi T. Carbohydrate differentiation antigens: probable ligands for cell adhesion molecules. Trends Biochem Sci 1991; 16:84-86.
70. Erdmann M, et al. Differential surface expression and possible function of 9-O- and 7-O-acetylated GD3 (CD60 b and c) during activation and apoptosis of human tonsillar B and T lymphocytes. Glycoconj J 2006; 23: 627-638.
71. Alessandri G, et al. Growth and motility of microvascular endothelium are modulated by the relative concentration of gangliosides in the medium. J Cell Physiol 1992; 151:23-28.
72. Tahiti S, Futerman AH. The metabolism and funtion of sphingolipids and glycosphingolipids. Cell Mol Life Sci 2007; 64: 2270-2284.
73. Schnaar RL. Glycolipid-mediated cell-cell recognition in inflammation and nerve regeneration. Arch Biochem Biophys 2004; 426: 163-172.
74. Stults CL, et al. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 1989; 179: 167-214
75. Müthing X Mammalian glycosphingolipids. In: Glycoscience: Chemistry and Chemical Biology. Vol 3. Heidelberg, Germany: Springer-Verlag 2001; 2220-2249.
76. Fantini J, et al. Glycosphingolipid (GSL) microdo-mains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretion. Glycoconj J 2000; 17: 173-179.
77. Hakomori SI. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J 2000; 17: 143-151.
78. Sonnino S, et al. Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem Rev 2006: 106: 2111-2125.
79. Simons K, Toomre D. Lipid rails and signal transduction. Nat Rev Mol Cell Biol 2000; 1:31-11.
80. Schnaar RL. Glycosphingolipids in cell surface recognition. Glycobiology 1991; 1: 477-485.
81. Feizi T. Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev 2000; 173: 79-88.
82. Russel RJ, et al. Avian and human receptor binding by hemagglutinins of influenza A viruses. Glycoconj J 2006; 23: 85-92.
83. Hidari KIPJ, et al. Binding kinetics of influenza viruses to sialic acid-containing carbohydrates. Glycoconj J 2007; 24: 583-590.
84. Karlsson KA. Animal glycosphingolipids as membrane attachment sites for bacteria. Annu Rev Biochem 1989; 58: 309-350.
85. Teneberg S, et al. Carbohydrate recognition by enterohemorrhagic Escherichia coli: characterization of a novel glycosphingolipid from cat small intestine. Glycobiology 2004; 14: 187-196.
86. Miller-Podraza Ft, et al. Novel binding epitope for Helicobacter pylori found in neolacto carbohydrate chains: structure and cross-binding properties. J Biol Chem 2005; 280: 19695-19703.
87. Usuki S, et al. Chemical validation of molecular mimicry: interaction of cholera toxin with Campylobacter lipooligosaccharides. Glycoconj J 2007; 24: 167-180.
88. 5 toxins. Curr Opin Struct Biol 1995; 5: 165-171.
89. Yowler BC, Schengrund CL. Glycosphingolipids -sweets for botulinum neurotoxin. Glycoconj J 2004; 21: 287-293.
90. Smith DC, et al. Glycosphingolipids as toxin receptors. Semin Cell Dcv Biol 2004; 15: 397-408.
91. Lingwood CA, et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 1987; 262: 8834-8839.
92. Waddell T, et al. Globotriosyl ceramide is specifically recognized by the Escherichia coli Verocytotoxin 2. Biochem Biophys Res Commun 1988; 152: 674-679.
93. Waddell T, et al. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriaosylceramide. Proc Natl Acad Sci USA 1990; 87: 7898-7901.
94. Head SC, et al. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 1991; 226: 3617-3621.
95. Nakajima H, et al. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem 2001; 276: 42915-12922.
96. Louise CB, Obrig, TG. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 1995; 172: 1397-1401.
97. Boyd B, et al. Lipid modulation of glycolipid receptor function. Eur J Biochem 1994; 223: 873-878.
98. Binnington B, et al. Effect of globotriaosylceramide fatty acid α-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem Res 2002; 27: 807-813.
99. Kiarash A, et al. Glycosphingolipid receptor function is modified by fatty acid content. J Biol Chem 1994; 269: 11138-1146.
100. Lingwood CA. Aglycone modulation of glycolipid receptor function. Glycoconj J 1996; 13: 495-503.
101. Sandvig K, et al. Importance of glycolipid synthesis for butyric acid-induced sensitization to Shiga toxin and intracellular sorting of toxin in A431 cells. Mol Biol Cell 1996; 7: 1391-1404.
102. DeGrandis S, et al. Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem 1989; 264: 12520-12525.
103. Samuel JE, et al. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect Immun 1990; 58: 611-618.
104. Waddell TE, et al. Interaction of verotoxin 2e with pig intestine. Infect Immun 1996; 64: 1714-1719.
105. Tyrrell GJ, et al. Alteration of the carbohydrate binding specificity of verotoxins from Galα1-4Gal to GalNAcßl-3Gala1 - 4Gαl and vice versa by site-directed mutagenesis of the binding subunit. Proc Natl Acad Sci USA 1992; 89: 524-528.
106. Boyd, B, et al. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1 -like disease in pigs. J Exp Med 1993; 177: 1745-1753.
107. Boyd B, Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron 1989; 51: 207-210.
108. Jacewicz M, et al. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect Immun 1999; 67: 1439-1444.
109. Ren J, et al. Localization of verotoxin receptors in nervous system. Brain Res 1999; 825: 183-188.
110. Obrig TO, et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988; 56: 2373-2378.
111. van Setten PA, et al. Effects of TNFα on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997; 51: 1245-1256.
112. Pudymaitis A, Lingwood CA. Susceptibility to verotoxin as a function of the cell cycle. J Cell Physiol 1992; 150: 632-639.
113. Majoul I, et al. Differential expression of receptors for Shiga and Cholera toxin is regulated by the cell cycle. J Cell Sci 2002; 115:817-826.
114. Obrig TG, et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993; 268: 15484-15488.
115. Gillard BK, et al. Association of glycosphingolipids with intermediate filaments of human umbilical vein endothelial cells. Exp Cell Res 1991; 192: 433-444.
116. Gillard BK. et al. Variable subcellular localization of glycosphingolipids. Glycobiology 1993; 3: 57-67.
117. Gillard BK, et al. Glycosphingolipids of human umbilical vein endothelial cells and smooth muscle cells. Arch Biochem Biophys 1987; 256: 435-445.
118. Müthing J, et al. Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. Glycobiology 1999; 9: 459-468.
119. Duvar S, et al. Isolation and structural characterization of glycosphingolipids of in vitro propagated bovine aortic endothelial cells. Glycobiology 1997; 7: 1099-1109.
120. Ohmi K, et al. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem Biophys Res Commun 1998; 251: 137-141.
121. SA, et al. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1ß enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993; 61: 3886-91.
122. Kanda T, et al. Glycosphingolipid composition of primary cultured human brain microvascular endothelial cells. J Neurosci Res 2004; 78: 141-150.
123. Duvar S, et al. Glycosphingolipid composition of a new immortalized human cerebromicrovascular endothelial cell line. J Neurochem 2000; 75: 1970-1976.
124. van de Kar NCAJ, et al. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80: 2755-2764.
125. van de Kar NCAJ, et al. Tumor necrosis factor α induces endothelial galactosyltransferase activity and verocytotoxin receptors. Role of specific tumor necrosis factor receptors and protein kinase C. Blood 1995; 85: 734-743.
126. Ramegowda B, et al. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis 1999; 180: 1205-1213.
127. 3 and sensitivity to Shiga toxin. Infect Immun 2001; 69: 1889-1894.
128. Stricklett PK, et al. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002; 186: 976-982.
129. Ergonul Z, et al. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J Infect Dis 2003; 187: 154-158.
130. O'Loughlm EV, Robins-Browne RM. Effect of Shiga-like toxins on eukaryotic cells. Microbes Infect 2001; 3: 493-507.
131. Müthing J. High-resolution thin-layer chromatography of gangliosides. J Chromatogr A 1996; 720: 3-25.
132. Müthing J. TEC in Structure and Recognition Studies of Glycosphingolipids. In: Glycoanalysis Protocols, Methods Mol Biol. Vol. 76 Humana Press Inc., Totowa, NJ 1998; 183-195.
133. Müthing J. TLC and HPLC of Glycosphingolipids. In: Carbohydrate Analysis by Modern Chromatography and Electrophoresis. J Chrom Libr. Vol. 66 Elsevier Science 2002; 423-482.
134. Müthing J, Heitmann D. Nondestructive detection of gangliosides with lipophilic fluorochromes and their employment for preparative high-performance thin-layer chromatography. Anal Biochem 1993; 208: 121-124.
135. Müthing J, Kemminer SE. Nondestructive detection of neutral glycosphingolipids with lipophilic anionic fluorochromes and their employment for preparative high-performance thin-layer chromatography. Anal Biochem 1996; 238: 195-202.
136. Meisen I, et al. Discrimination of neolacto-series gangliosides with α2-3- and α2-6-linked N-acetyl-neuraminic acid by nanoelectrospray ionization low-energy collision-induced dissociation tandem quad-rupole TOF MS. Anal Chem 2003; 75: 5719-5725.
137. Edgell C-JS, et al. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80: 3734-3737.
138. Stins MF, et al. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 1997; 76: 81-90.
139. Schweppe CH, et al. Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J 2008; 25: 291-304.
140. Levery SB. Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol 2005; 405: 300-369.
141. Harvey DJ. Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update covering the period 1999-2000. Mass" Spectrum Rev 2006; 25: 595-662.
142. Meisen I, et al. Direct analysis of silica gel extracts from immunostained glycosphingolipids by nanoelectrospray ionization quadrupole lime-of-flight mass spectrometry. Anal Chem 2004; 76: 2248-2255.
143. Meisen I, et al. Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionisation quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. Rapid Commun Mass Spectrom 2005; 19: 3659-3665.
144. Müthing J. Analyses of glycosphingolipids by high-performance liquid chromatography. Methods Enzymol 2000; 312: 45-64.
145. Sandvig K, et al. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMR J Cell Biol 1994; 126: 53-64.
146. Seldno T, et al. Characterization of a Shiga-toxin 1-resistant stock of vero cells. Microbiol Immunol 2004; 48: 377-387.
147. Dreisewerd K, et al. Analysis of gangliosides directly from thin-layer chromatography plates by infrared matrix-assisted laser desorption/ionization orthogonal lime-of-flight mass spectrometry with a glycerol matrix. Anal Chem 2005; 77: 4098-4107.
148. Distler U, et al. Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer. Anal Chem 2008; 80: 1835-1846.
149. Lingwood CA. Verotoxin-binding in human renal sections. Nephron 1994; 66: 21-28.
150. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
151. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 17221-17224.
152. Anderson ROW, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 2002; 296: 1821-1825.
153. Kasahara K, Sanai Y. Functional roles of glycosphingolipids in signal transduction via lipid rafts. Glycoconj J 2000; 17: 153-162.
154. Hoessli DC, et al. Signaling through sphingolipid microdomains of the plasma membrane: The concept of signaling platform. Glycoconj J 2000; 17: 191-197.
155. Cohen AW, et al. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379.
156. Hommelgaard AM, et al. Caveolae: stable membrane domains with a potential for internalization. Traffic 2005; 6: 720-724.
157. Stan RV Structure and function of endothelial caveolae. Microsc Res Tech 2002; 57: 350-364.
158. Frank PG, et al. Caveolin, caveolae, and endothelial cell function. Arlerioscler Thromb Vasc Biol 2003; 23: 1161-1168.
159. Lopez JA, et al. Receptors, rafts, and microve-sicles in thrombosis and inflammation. J Thromb Haemost 2005; 3: 1737-1744.
160. Nabi IR, Le PU. Caveolae/raft-dependent endocytosis. J Cell Biol 2003; 161: 673-677.
161. Parlon RG, Richards AA. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 2003; 4: 724-738.
162. Kovbasnjuk O, et al. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci 2001; 114: 4025-4031.
163. Falguières T, et al. Targeting of Shiga toxin B-sub-unit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell 2001; 12: 2453-2468.
164. KatagiriYU, et al. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem 1999; 274: 35278-35282.
165. Takenouchi H, et al. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J Cell Sci 2004; 117: 3911-3922.
166. Smith DC, et al. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell 2006; 17: 1375-1387.
167. Falguières T, et al. Functionally different pools of Shiga toxin receptor, globotriaosyl ceramide, in HeLa cells. FEBS J 2006; 273: 5205-5218.
168. 5 subunit bacterial toxins. Biochim Biophys Acta 2005; 1746: 314-321.
169. Gaus K, et al. Visualizing lipid structure and raft domains in living cells with two-photon microscopy. Proc Natl Acad Sci USA 2003; 100: 15554-15559.
170. Kemper B, et al. Investigation of living pancreas tumor cells by digital holographic microscopy. J Biomed Opt 2006; 11:34005.
171. Müthing J, et al. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Acα2-6Galß1 -4GlcNAc residues. Biochemistry 2004; 43: 2996-3007.
172. Gerber A, et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186: 493-500.
173. Banatvala N, et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183: 1063-1070.
174. Tozzi AE, et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. Emerg Infect Dis 2003; 9: 106-108.